Galantamine

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: memory focus longevity

Research Overview

Research on galantamine has been most concentrated in symptomatic treatment of Alzheimer’s disease (AD) within the broader class of cholinesterase inhibitors (ChE-Is), focusing on short-term outcomes in cognition, global clinical change, and functional measures, as well as tolerability—particularly gastrointestinal adverse effects. Comparative and pooled analyses frequently evaluate galantamine alongside donepezil and rivastigmine, reflecting an emphasis on relative efficacy within the ChE-I class and on dose–response (commonly 16–24 mg/day, with some analyses including 32 mg/day). A secondary but notable area of study is extension of ChE-Is to non-AD dementias, especially vascular cognitive impairment (VCI), based on shared cholinergic deficits, and exploration of combination strategies (e.g., with NMDA antagonists or antioxidants), although these combination approaches are described more as investigational directions than as established practice in the studies reviewed here.

The strongest evidence supports that galantamine produces statistically significant but modest symptomatic benefits on cognition in AD, with pooled trial data indicating measurable improvements versus placebo; however, multiple sources emphasize that the magnitude of benefit is generally mild and may not always be clinically meaningful. Evidence also supports small benefits on some non-cognitive outcomes in AD (e.g., limited behavioral/global measures in certain dose groups), but effects appear less consistent than cognitive outcomes. In VCI, moderate-certainty evidence indicates galantamine (16–24 mg/day) probably improves cognition slightly versus placebo, though the effect size is again unlikely to be clinically important. Across indications, galantamine is associated with increased adverse events and higher dropout risk compared with placebo, with gastrointestinal symptoms prominently reported, consistent with class effects of ChE-Is.

Key gaps include better characterization of clinical meaningfulness (e.g., patient-centered functional outcomes, quality of life, caregiver burden, and longer-term trajectories) and clearer identification of subgroups most likely to benefit (by disease stage, comorbidity profile, or biomarker-defined pathology). More research is also needed on optimizing tolerability and delivery to mitigate adverse effects (including formulation and dosing strategies) and on rigorously tested combination regimens, since combination therapy is highlighted as a potential avenue but not established by the summarized evidence. In VCI specifically, further trials would help refine comparative effectiveness versus other ChE-Is and clarify benefit–harm tradeoffs over longer follow-up, given that observed cognitive gains are small and adverse events are more frequent than with placebo.

1. What conditions has Galantamine been studied for?

  • Alzheimer’s disease (AD) (adult-onset dementia): discussed as one of the currently marketed cholinesterase inhibitors for symptomatic treatment of AD.

  • Vascular cognitive impairment (VCI), including vascular dementia and post-stroke cognitive impairment: evaluated in randomized controlled trials summarized in a Cochrane review/network meta-analysis (galantamine 16–24 mg/day).

  • Combination therapy contexts in dementia: mentioned as being investigated in combination with other drug classes (e.g., NMDA receptor antagonists, antioxidants), though the studies reviewed here do not give galantamine-specific trial outcomes for combinations.

2. Does it work in treating those conditions? Summarize the evidence.

  • Alzheimer’s disease: Evidence across placebo-controlled trials/meta-analyses indicates statistically significant cognitive benefits versus placebo, but the clinical magnitude is debated and often described as mild.

    • In a pooled analysis of double-blind placebo-controlled trials, the 32 mg/day galantamine group showed a cognitive mean difference of -3.20 points (95% CI -3.28 to -3.12) versus placebo (scale not specified in the study, but reported as a cognitive outcome).

    • Another review notes that cholinesterase inhibitors (including galantamine) have similar efficacy overall and that benefit is mild and may not be clinically significant.

    • A health technology assessment for AD concluded the evidence continues to suggest clinical benefit in alleviating AD symptoms, while acknowledging debate about effect size and limitations such as short trial duration (≤6 months) and incomplete outcome reporting.

  • Vascular cognitive impairment / vascular dementia: Evidence suggests small improvements in cognition that are unlikely to be clinically important, with increased adverse events versus placebo.

    • Cochrane review (8 trials; 4373 participants): galantamine 16–24 mg/day probably improves cognition versus placebo: ADAS-Cog MD -2.01 points (range 0–70), 95% CI -3.18 to -0.85; moderate-certainty evidence. Authors note the effect size may not be clinically important.

3. What health benefits does it have?

  • Cognition (primary consistent benefit):

    • In AD, galantamine shows statistically significant cognitive benefit versus placebo in pooled trial evidence (e.g., reported mean difference -3.20 for 32 mg/day in one pooled analysis).

    • In VCI, galantamine probably improves cognition slightly (ADAS-Cog MD -2.01; moderate-certainty), though the review emphasizes the change is unlikely to be clinically important.

  • Behavior/global outcomes (limited and inconsistent):

    • In the pooled AD drug analysis, behavioral benefit was generally not observed, but there was a reported behavioral effect for 24 mg/day galantamine: -1.72 (95% CI -3.12 to -0.33) on a behavioral outcome (scale not specified in the study).

    • Across AD drugs as a class, cholinesterase inhibitors are described as able to stabilize or slow decline in cognition/function/behavior/global change, but the studies emphasize that effects are typically modest.

4. Does it have any downsides or side effects?

  • Adverse events and tolerability: Compared with placebo, cholinesterase inhibitors (including galantamine) are associated with more adverse events and more dropouts in pooled placebo-controlled trial evidence.

  • Common side effects reported in VCI trials: nausea/vomiting, diarrhea, dizziness, headache, and hypertension.

  • Quantified harm signal in VCI: galantamine 16–24 mg/day is probably associated with a slight excess of adverse events versus placebo: OR 1.57 (95% CI 1.02 to 2.43); moderate-certainty evidence.

  • Clinical trade-off: The studies repeatedly frame benefits as modest and sometimes not clinically significant, which matters when weighing side effects (especially gastrointestinal effects) and discontinuation risk.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings for galantamine (e.g., outcomes by genotype, metabolizer status, or receptor variants). Therefore:

  • No evidence from these studies that specific genetic variations make galantamine more beneficial or more harmful.

  • Limitation: Absence of pharmacogenomic detail in these summaries does not mean no such effects exist; it only means they are not addressed in the provided evidence.

References

  1. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
    Gabriella Marucci, Michela Buccioni, Diego Dal Ben, Catia Lambertucci, Rosaria Volpini, Francesco Amenta (2021) - Neuropharmacology
  2. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Chen-Chen Tan, Jin-Tai Yu, Hui-Fu Wang, Meng-Shan Tan, Xiang-Fei Meng, Chong Wang, Teng Jiang, Xi-Chen Zhu, Lan Tan (2014) - Journal of Alzheimer's disease : JAD
  3. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Ceri E Battle, Azmil H Abdul-Rahim, Susan D Shenkin, Jonathan Hewitt, Terry J Quinn (2021) - The Cochrane database of systematic reviews
  4. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
    Filip Zemek, Lucie Drtinova, Eugenie Nepovimova, Vendula Sepsova, Jan Korabecny, Jiri Klimes, Kamil Kuca (2014) - Expert opinion on drug safety
  5. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    M Bond, G Rogers, J Peters, R Anderson, M Hoyle, A Miners, T Moxham, S Davis, P Thokala, A Wailoo, M Jeffreys, C Hyde (2012) - Health technology assessment (Winchester, England)
  6. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
    Sagheer Ahmed, Sidrah Tariq Khan, Muhammad Kazim Zargaham, Arif Ullah Khan, Saeed Khan, Abrar Hussain, Jalal Uddin, Ajmal Khan, Ahmed Al-Harrasi (2021) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  7. The involvement of neuroinflammation in an animal model of dementia and depression.
    Gabriel Casagrande Zabot, Eduarda Behenck Medeiros, Bárbara Machado Naspolini Macarini, Bruno Búrigo Peruchi, Gabriela Serafim Keller, Adrielly Vargas Lídio, Amanda Boaventura, Laura Ceolin de Jesus, Gustavo de Bem Silveira, Paulo Cesar Lock Silveira, Beatriz Costa Chede, Gislaine Zilli Réus, Josiane Budni (2024) - Progress in neuro-psychopharmacology & biological psychiatry
  8. Potential Therapeutic Applications of Plant-Derived Alkaloids against Inflammatory and Neurodegenerative Diseases.
    Babita Aryal, Bimal Kumar Raut, Salyan Bhattarai, Sobika Bhandari, Parbati Tandan, Kabita Gyawali, Kabita Sharma, Deepa Ranabhat, Ranjita Thapa, Dipa Aryal, Atul Ojha, Hari Prasad Devkota, Niranjan Parajuli (2022) - Evidence-based complementary and alternative medicine : eCAM
  9. Pharmacotherapy for Vascular Cognitive Impairment.
    Muhammad U Farooq, Jiangyong Min, Christopher Goshgarian, Philip B Gorelick (2017) - CNS drugs
  10. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Muriel Noetzli, Chin B Eap (2013) - Clinical pharmacokinetics
  11. Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression.
    Shaikh Sheeran Naser, Dibyangshee Singh, Subham Preetam, Shristi Kishore, Lamha Kumar, Aditya Nandi, Faizan Zarreen Simnani, Anmol Choudhury, Adrija Sinha, Yogendra Kumar Mishra, Mrutyunjay Suar, Pritam Kumar Panda, Sumira Malik, Suresh K Verma (2023) - Materials today. Bio
  12. Cholinergic Control of Inflammation, Metabolic Dysfunction, and Cognitive Impairment in Obesity-Associated Disorders: Mechanisms and Novel Therapeutic Opportunities.
    Eric H Chang, Sangeeta S Chavan, Valentin A Pavlov (2019) - Frontiers in neuroscience
  13. Inhibition mechanism of fisetin on acetylcholinesterase and its synergistic effect with galantamine.
    Wenli Shi, Wenxin Han, Yijing Liao, Jiaqi Wen, Guowen Zhang (2024) - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  14. Effect of high-frequency (5Hz) rTMS stimulating left DLPFC combined with galantamine on cognitive impairment after ischemic stroke and serum homocysteine and neuron-specific enolase.
    Guojin Hu, Li Zhang, Xiuli Sun, Lin Wang, Qian Xu, Qin Li, Wei Huang, Yao Xiao (2024) - Frontiers in neurology
  15. A Comprehensive Analysis on Galantamine Based Hybrids for the Management of Alzheimer's Disease.
    Yash Pal Singh, Sonima Prasad, Harish Kumar (2024) - Chemical biology & drug design
  16. A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia.
    Caterina Tezze, Francesco Ivan Amendolagine, Leonardo Nogara, Martina Baraldo, Stefano Ciciliot, Diletta Arcidiacono, Alice Zaramella, Giulio Masiero, Giulia Ferrarese, Stefano Realdon, Bert Blaauw, Giel Detienne, Ann Tj Beliën, Marco Sandri, Evi M Mercken (2023) - JCI insight
  17. Acetylcholinesterase inhibitors for autistic spectrum disorders.
    Alexandra Ure, Georgina R Cox, Richard Haslam, Katrina Williams (2023) - The Cochrane database of systematic reviews
  18. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
    Amanda Wei Yin Lim, Lon Schneider, Clement Loy (2024) - The Cochrane database of systematic reviews
  19. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.
    Yukio Ago, Ken Koda, Kazuhiro Takuma, Toshio Matsuda (2011) - Journal of pharmacological sciences
  20. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
    Dana Mohammad, Parco Chan, Janelle Bradley, Krista Lanctôt, Nathan Herrmann (2017) - Expert opinion on drug safety


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!